selected publications
-
Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial.
JAMA oncology.
2018
Academic Article
GET IT
Times cited: 46 -
A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer.
Investigational new drugs.
2018
Academic Article
GET IT
Times cited: 61 -
Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.
Annals of oncology : official journal of the European Society for Medical Oncology.
2017
Academic Article
GET IT
Times cited: 74 -
Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
European urology.
2017
Academic Article
GET IT
Times cited: 22 -
Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2017
Academic Article
GET IT
Times cited: 78 -
Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL.
Prostate cancer and prostatic diseases.
2017
Academic Article
GET IT
Times cited: 74 -
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.
European urology.
2016
Academic Article
GET IT
Times cited: 334 -
Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
European urology.
2016
Academic Article
GET IT
Times cited: 72 -
Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort.
European urology.
2016
Academic Article
GET IT
Times cited: 111 -
Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.
European urology.
2016
Academic Article
GET IT
Times cited: 35 -
Phase Ib Study of Enzalutamide in Combination with Docetaxel in Men with Metastatic Castration-Resistant Prostate Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2016
Academic Article
GET IT
Times cited: 24 -
A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel.
Annals of oncology : official journal of the European Society for Medical Oncology.
2015
Academic Article
GET IT
Times cited: 144 -
Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase III trials.
Annals of oncology : official journal of the European Society for Medical Oncology.
2015
Academic Article
GET IT
Times cited: 41 -
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies.
European urology.
2015
Academic Article
GET IT
Times cited: 22 -
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
Cancer.
2015
Academic Article
GET IT
Times cited: 28 -
Novel and next-generation androgen receptor-directed therapies for prostate cancer: Beyond abiraterone and enzalutamide.
Urologic oncology.
2015
Information Resource
GET IT
Times cited: 26 -
Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.
The Journal of urology.
2015
Academic Article
GET IT
Times cited: 65 -
A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer.
European journal of cancer.
2015
Academic Article
GET IT
Times cited: 26 -
Integrative clinical genomics of advanced prostate cancer.
Cell.
2015
Academic Article
GET IT
Times cited: 2536 -
Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302.
European urology.
2015
Academic Article
GET IT
Times cited: 54 -
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America.
The Prostate.
2015
Academic Article
GET IT
Times cited: 20 -
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.
The Lancet. Oncology.
2015
Academic Article
GET IT
Times cited: 799 -
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2015
Academic Article
GET IT
Times cited: 50 -
Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2014
Academic Article
GET IT
Times cited: 112 -
Organoid cultures derived from patients with advanced prostate cancer.
Cell.
2014
Academic Article
GET IT
Times cited: 1164 -
Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
Oncology (Williston Park, N.Y.).
2014
Information Resource
GET IT
Times cited: 18 -
Enzalutamide in metastatic prostate cancer before chemotherapy.
The New England journal of medicine.
2014
Academic Article
GET IT
Times cited: 2122 -
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).
European urology.
2014
Academic Article
GET IT
Times cited: 264 -
Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.
European urology.
2014
Academic Article
GET IT
Times cited: 30 -
First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer.
British journal of cancer.
2013
Academic Article
GET IT
Times cited: 75 -
A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer.
Cancer chemotherapy and pharmacology.
2013
Academic Article
GET IT
Times cited: 80 -
Repetitively dosed docetaxel and ¹⁵³samarium-EDTMP as an antitumor strategy for metastatic castration-resistant prostate cancer.
Cancer.
2013
Academic Article
GET IT
Times cited: 23 -
Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.
European journal of nuclear medicine and molecular imaging.
2013
Academic Article
GET IT
Times cited: 154 -
Repurposing itraconazole as a treatment for advanced prostate cancer: a noncomparative randomized phase II trial in men with metastatic castration-resistant prostate cancer.
The oncologist.
2013
Academic Article
GET IT
Times cited: 156 -
Androgen receptor antagonists in castration-resistant prostate cancer.
Cancer journal (Sudbury, Mass.).
2013
Information Resource
GET IT
Times cited: 115 -
Abiraterone in metastatic prostate cancer without previous chemotherapy.
The New England journal of medicine.
2012
Academic Article
GET IT
Times cited: 2417 -
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer.
Annals of oncology : official journal of the European Society for Medical Oncology.
2012
Academic Article
GET IT
Times cited: 30 -
A phase I trial of docetaxel and pulse-dose 17-allylamino-17-demethoxygeldanamycin in adult patients with solid tumors.
Cancer chemotherapy and pharmacology.
2011
Academic Article
GET IT
Times cited: 31 -
Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2010
Academic Article
GET IT
Times cited: 39 -
A phase I pharmacokinetic study of pulse-dose vorinostat with flavopiridol in solid tumors.
Investigational new drugs.
2010
Academic Article
GET IT
Times cited: 33 -
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.
Lancet (London, England).
2010
Academic Article
GET IT
Times cited: 969 -
A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.
Cancer chemotherapy and pharmacology.
2010
Academic Article
GET IT
Times cited: 92 -
A phase I clinical trial of FOLFIRI in combination with the pan-cyclin-dependent kinase (CDK) inhibitor flavopiridol.
Cancer chemotherapy and pharmacology.
2010
Academic Article
GET IT
Times cited: 26 -
Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium.
Cancer.
2009
Academic Article
GET IT
Times cited: 127 -
Phase I study of flavopiridol with oxaliplatin and fluorouracil/leucovorin in advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2009
Academic Article
GET IT
Times cited: 48 -
Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2009
Academic Article
GET IT
Times cited: 84 -
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2008
Academic Article
GET IT
Times cited: 23 -
Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2007
Academic Article
GET IT
Times cited: 74